- Home
- SKYE vs SRBK Comparison
SKYE vs SRBK Comparison
Compare SKYE & SRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- SRBK
- Stock Information
- Founded
- SKYE 2012
- SRBK 1887
- Country
- SKYE United States
- SRBK United States
- Employees
- SKYE N/A
- SRBK N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- SRBK
- Sector
- SKYE Health Care
- SRBK
- Exchange
- SKYE Nasdaq
- SRBK Nasdaq
- Market Cap
- SKYE 115.9M
- SRBK 117.4M
- IPO Year
- SKYE N/A
- SRBK N/A
- Fundamental
- Price
- SKYE $3.41
- SRBK $13.96
- Analyst Decision
- SKYE Buy
- SRBK
- Analyst Count
- SKYE 6
- SRBK 0
- Target Price
- SKYE $16.60
- SRBK N/A
- AVG Volume (30 Days)
- SKYE 467.4K
- SRBK 55.6K
- Earning Date
- SKYE 08-07-2025
- SRBK 07-31-2025
- Dividend Yield
- SKYE N/A
- SRBK 1.44%
- EPS Growth
- SKYE N/A
- SRBK N/A
- EPS
- SKYE N/A
- SRBK 0.44
- Revenue
- SKYE N/A
- SRBK $31,833,000.00
- Revenue This Year
- SKYE N/A
- SRBK N/A
- Revenue Next Year
- SKYE N/A
- SRBK N/A
- P/E Ratio
- SKYE N/A
- SRBK $31.73
- Revenue Growth
- SKYE N/A
- SRBK 39.53
- 52 Week Low
- SKYE $1.14
- SRBK $9.50
- 52 Week High
- SKYE $7.47
- SRBK $14.96
- Technical
- Relative Strength Index (RSI)
- SKYE 44.99
- SRBK 48.02
- Support Level
- SKYE $3.45
- SRBK $13.55
- Resistance Level
- SKYE $3.84
- SRBK $14.55
- Average True Range (ATR)
- SKYE 0.35
- SRBK 0.27
- MACD
- SKYE -0.12
- SRBK -0.10
- Stochastic Oscillator
- SKYE 13.91
- SRBK 34.17
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About SRBK SR Bancorp Inc. Common stock
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.